Thrombosis and Haemostasis, Table of Contents Thromb Haemost 1986; 55(03): 375-378DOI: 10.1055/s-0038-1661567 Original Article Schattauer GmbH Stuttgart α2-Antiplasmin: Functional Characterization and Metabolism in a Heterozygote Deficient Patient Authors Author Affiliations E A R Knot The Departments of Haematology, Division of Haemostasis and Thrombosis, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands J W ten Cate The Departments of Haematology, Division of Haemostasis and Thrombosis, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands R J Lamping The Departments of Haematology, Division of Haemostasis and Thrombosis, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands Liem Kian Gie The Departments of Haematology, Division of Haemostasis and Thrombosis, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands Recommend Article Abstract PDF Download(opens in new window) Buy Article(opens in new window) Summary An 81-year-old male with a mild life-long bleeding history and an α2-antiplasmin (α2-AP) plasma level of 55% biological activity and 41% antigen activity (normal range 80-140%) was studied. The ratio of plasminogen binding (PB): non-plasminogen binding (NPB) α2-AP assayed by modified crossed immunoelectrophoresis (CIE) was 7.3/2.7 (controls 6.3 ± 0.49 SD/3.7 ± 0.49 SD). The patient’s α2-AP showed decreased affinity for fibrin, i. e. 8.3% versus 32.4% of normal control α2-AP associated with fibrin during clotting of plasma. A metabolic study performed with human purified 125I-α2-AP(PB/NPB 7.7/2.3) showed a plasma radioactivity disappearance half-life of 72.9 h (n 60.1 ± 5.3 h) with a normal fractional catabolic rate and a reduced absolute catabolic (synthetic) rate of 0.70 mg/kg/day (n 2.10 ± 0.60 mg/kg/day). The exchange between the central and third compartment was increased. The increased α2-AP PB form and the increased plasma radioactivity disappearance half-life are suggestive of a slower conversion of the PB form into the NPB form and/or slower degradation of the PB form. The bleeding tendency in this patient could be explained by decreased synthesis of α2-AP and decreased binding to fibrin. Keywords Keywordsα2-Antiplasmin metabolism - Characterization - Heterozygote deficiency PDF (1486 kb) References References 1 Collen D. Identification and some properties of a new fast reacting plasma inhibitor in human plasma. Eur J Biochem 1976; 69: 209-216 2 Moroi M, Aoki N. Isolation and characterization of α2-plasmin inhibitor from human plasma. J Biol 1976; 251: 5956-5965 3 Miillertz S, Clemmensen I. The primary inhibitor of plasmin in human plasma. Biochem J 1976; 159: 545-553 4 Wiman B, Collen D. Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma. Eur J Biochem 1977; 78: 19-26 5 Collen D, Wiman B. Fast-acting plasma inhibitor in human plasma. Blood 1978; 51: 563-569 6 Clemmensen I. Different molecular forms of α2-antiplasmin. In: The physiological inhibitors of coagulation and fibrinolysis Collen D, Wiman B, Verstraete M. (eds.) pp 131-136 Elsevier North Holland. Paramedical Press; Amsterdam: 1979 7 Wiman B. Affinity-chromatographic purification of human α2-anti-plasmin. Biochem J 1980; 191: 229-232 8 Sakata Y, Aoki N. Cross-linking of α2-antiplasmin inhibitor to fibrin stabilizing factor. J Clin Invest 1980; 65: 290-297 9 Tamaki T, Aoki N. Cross-linking of α2-antiplasmin inhibitor and fibronectin to fibrin by fibrin stabilizing factor. Biochem Biophys Acta 1981; 661: 280-286 10 Christensen U, Clemmensen I. Purification and reaction mechanisms of the primary inhibitor of plasma from human plasma. Biochem J 1978; 175: 635-641 11 Bagge L, Saldeen T. The primary fibrinolysis inhibitor and trauma. Thromb Res 1978; 13: 1131-1136 12 Clemmensen I, Thorsen S, Miillertz S, Petersen LC. Properties of three different molecular forms of the α2-antiplasmin inhibitor. Eur J Biochem 1981; 120: 105-112 13 Kluft C, Los P. Demonstration of two forms of α2-antiplasmin in plasma by modified crossed immunoelectrophoresis. Thromb Res 1981; 21: 65-71 14 Kluft C, Los P, Jie AF H, Van Hinsbergh VW M, Vellenga E, Jespersen J, Henny ChP. The mutual relation of the two molecular forms of the major fibrinolysis inhibitor, α2-antiplasmin in blood. Blood 1986; 67: 616-622 15 Kluft C, Los P, Jie AF H. The molecular form of α2-antiplasmin with affinity for plasminogen selectively bound to fibrin by factor XIII. Thromb Res 1984; 33: 419-425 16 Saito H, Goodnough LT, Knowles BB, Aden DP. Synthesis and secretion of α2-plasmin inhibitor by established human liver cell lines. Proc Natl Acad Sci 1982; 79: 5684-5687 17 Hogstrop H, Saldeen T. Synthesis of α2-antiplasmin by rat liver cells. Thromb Res 1982; 28: 19-25 18 Koie K, Kamiya T, Ogata K, Takamatsu J, Kobakura M. α2-plasmin inhibitor deficiency (Miyasato disease). Lancet 1978; 2: 1334-1336 19 Aoki N, Saito H, Kamiya T, Koie K, Sakata Y, Kobakura M. Congenital deficiency of α2-antiplasmin inhibitor associated with severe hemorrhagic tendency. J Clin Invest 1979; 63: 877-884 20 Aoki N, Sakata Y, Matsuda M, Tateno K. Fibrinolytic states in a patient with congenital deficiency of α2-plasmin inhibitor. Blood 1980; 55: 483-488 21 Yoshioka A, Kamitsuji H, Takase T, Iida Y, Tsukada S, Mikami S, Fukui H. Congenital deficiency of α2-plasmin inhibitor in three sisters. Haemostasis 1982; 11: 176-184 22 Kluft C, Vellenga E, Brommer EJ P. Homozygous α2-antiplasmin deficiency. Lancet 1979; 2: 206 23 Kluft C, Vellenga E, Brommer EJ P, Wijngaards G. A familial hemorrhagic diathesis in a Dutch family: An inherited deficiency of α2-antiplasmin. Blood 1982; 59: 1169-1180 24 Miles LA, Plow EF, Donnelly KJ, Hougie C, Griffin JH. A bleeding disorder due to deficiency of α2-antiplasmin. Blood 1982; 59: 1246-1257 25 Stormorken H, Gogstad GO, Brosstad F. Hereditary α2-antiplasmin deficiency. Thromb Res 1983; 31: 647-651 26 Peters M, Breederveld C, Kahle LH, Ten Cate JW. Rapid microanalysis of coagulation parameters by automated chromogenic substrated methods. Application in neonatal patients. Thromb Res 1983; 28: 773-781 27 Muszbek L, Polgar J, Fesus L. Kinetic determination of blood coagulation factor XIII in plasma. Clin Chem 1985; 31: 35-41 28 Laurell CB. Quantitative estimations of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52 29 Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single radial immuno diffusion. Immunochemistry 1965; 2: 235-254 30 Weeke B. Crossed immunoelectrophoresis. In: A manual of quantitative immunoelectrophoresis Axelsen NH, Krøll J, Weeke B. (eds.) pp 47-56 Universiteits forlaget; Oslo: 1973 31 Collen D, Wiman B. Turnover of antiplasmin in the fast-acting plasmin inhibitor of plasma. Blood 1979; 53: 313-324 32 Knot EA R, Drijfhout HR, Ten Cate JW, de Jong E, Iburg AH C, Kahle LH, Grijm R. α2-Plasmin inhibitor metabolism in patients with liver cirrhosis. J Lab Clin Med 1985; 105: 353-361 33 Salacinski PR P, Lean McC, Sykes JE C, Clement-Jones VV, Lowry PJ. Iodination of proteins, glycoproteins and peptides using a solidphase oxidizing agent 1, 3, 4, 6, tetrachloro-3α, 6α diphenyl glycoluril (Iodogen). Anal Biochem 1981; 117: 136-146 34 Matthews CM E. The theory of tracer experiments with 131I-labelled plasma proteins. Phys Med Biol 1957; 2: 36-53 35 Tamaki T, Sakata Y, Aoki N. Survival of transfused α2-plasmin inhibitor in a patient with its congenital deficiency. Thromb Res 1981; 22: 281-286
